Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Interventional
Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Overall Survival
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
CSMS995BFR04
NCT00241020
June 2002
March 2008
Name | Location |
---|